JAK/TYK2

      PsA.Hands_.jpg
      The Need for Comparative Treatment Trials in Psoriatic Arthritis
      4 years ago
      Psoriatic arthritis is currently experiencing a burgeoning selection of treatment options. While this is a very welcome development in a disease which has had less treatment options compared to RA, it leaves us with a difficult conundrum: which agent to choose for an individual patient.
      RT @drdavidliew: Will a FDA black box warning change your JAKi practice?

      In May 2019, the EMA put out a warning about V

      David Liew drdavidliew

      4 years ago
      Will a FDA black box warning change your JAKi practice? In May 2019, the EMA put out a warning about VTE with tofacitinib. In this French cohort, did it change the kind of pts they initiated on JAKi? no, not it did not😊 A window into the US future? #ACR21 ABST1245 @RheumNow https://t.co/QI95E1gepg
      RT @DrMiniDey: Safety profile of #upadacitinib in #RA, #PsA, #AnkylosingSpondylitis
      👉🏼AE rates similar across UPA

      Mrinalini Dey DrMiniDey

      4 years ago
      Safety profile of #upadacitinib in #RA, #PsA, #AnkylosingSpondylitis 👉🏼AE rates similar across UPA, ADA & MTX in RA, and UPA & ADA in PsA 👉🏼No new safety risks with long-term use 👉🏼#Herpeszoster & incr CPK more common w/ UPA vs ADA/MTX Abs#1691 #ACR21 @RheumNow https://t.co/tKYi65kB5r
      RA Treatment Conundrums: Dr. Janet Pope
      4 years ago
      Autoinflammatory: PAH in AOSD, VEXAS, JAKi in Still's, Role of labs in infections vs. flares
      4 years ago
      FDA Session Review: Dr. Arthur Kavanaugh
      4 years ago
      ACR Best
      ACR21 Best Abstracts We Saw - Day 3 (Monday)
      4 years ago
      The third day of ACR 2021 took a big leap in online content.  Here is a compilation (with links) of presentations were the “ACRBest” as seen by our RheumNow faculty. 
      RT @_Castillo_Pedro: Upadacitinib 56-wk efficacy/safety (mod to severe PsA)
      🔹Comparable or ⬆️efficacy vs adalimum

      Pedro Castillo _Castillo_Pedro

      4 years ago
      Upadacitinib 56-wk efficacy/safety (mod to severe PsA) 🔹Comparable or ⬆️efficacy vs adalimumab 🔹Efficacy maintained, and 15mg vs 30mg doses similar at 56wks 🔹No new safety findings @ 56wks 🔹🚫inc risk VTE, MACE, cancer vs ada https://t.co/NlKvBrwDxB #ACR21 Abst#1345 @RheumNow
      RT @drdavidliew: Interesting question came up: why would you change a RA patient from JAKi to JAKi?

      The main reason I c

      David Liew drdavidliew

      4 years ago
      Interesting question came up: why would you change a RA patient from JAKi to JAKi? The main reason I can think of would be if the first JAKi worked a bit (but not enough to continue, or AEs got in the way). That would clearly favour to better survival #ACR21 ABST1442 @RheumNow https://t.co/kDiJVbJfit
      RT @RichardPAConway: JAK-pot registry-based study. Following JAKi failure should you switch mode of action or go to seco

      Richard Conway RichardPAConway

      4 years ago
      JAK-pot registry-based study. Following JAKi failure should you switch mode of action or go to second JAKi? Both seem equally effective in terms of drug retention. Didn't matter if switch for efficacy or adverse event. Abstr#1442 #ACR21 @RheumNow https://t.co/QEBB3flArC
      RT @ericdeinmd: #ACR21 Abs#1442: JAKpot - Cycle JAK or switch to bDMARD after JAK failure?
      ▶️No difference between c

      Eric Dein ericdeinmd

      4 years ago
      #ACR21 Abs#1442: JAKpot - Cycle JAK or switch to bDMARD after JAK failure? ▶️No difference between cycle vs bDMARD group ▶️Non-signif trends: cycled JAK better for inefficacy to 1st JAK, bDMARD better for adverse effects @Rheumnow https://t.co/6UNUVh5ZW8 https://t.co/upfI6tDH1p
      RT @AurelieRheumo: First JAKi failure: What's next? Wanna find out? It's here
      https://t.co/o5CE1MBzUu
      Abstr#1442 #ACR21

      Aurelie Najm AurelieRheumo

      4 years ago
      First JAKi failure: What's next? Wanna find out? It's here https://t.co/o5CE1MBzUu Abstr#1442 #ACR21 @RheumNow https://t.co/f0sdPn5mcZ
      RT @AurelieRheumo: ⭐️ Wanna catch up with the latest news on JAKi safety trials presented at #ACR21? Our @Rheumnow i

      Aurelie Najm AurelieRheumo

      4 years ago
      ⭐️ Wanna catch up with the latest news on JAKi safety trials presented at #ACR21? Our @Rheumnow interview with @ErnestChoy1 is out. Link below https://t.co/zYb4rXcw1x https://t.co/i39xXnfC3Q
      JAKi Safety: Dr. Ernest Choy with Dr. Aurelie Najm
      4 years ago
      RT @doctorRBC: Post-hoc analysis of Deucravacitinib (TYK2i) for tx of PsA showed similar efficacy in pts with and withou

      Robert B Chao, MD doctorRBC

      4 years ago
      Post-hoc analysis of Deucravacitinib (TYK2i) for tx of PsA showed similar efficacy in pts with and without background csDMARD use. ⭐️>60% w/ background csDMARD use, majority of which was MTX ⭐️no difference in AE #ACR21 Abs#1352 @RheumNow https://t.co/nIJT7rNkJP https://t.co/bq0x1Ywguo

      Catch up on Conference Podcasts

      ×